Navigation Links
Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia
Date:12/8/2009

hood of relapse," commented Professor D. Hoelzer, chairman of the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL). "These data suggest that blinatumomab is very active and has the potential to be an effective consolidation therapy."

"The data from this completed phase 2 study confirm the high response rate reported earlier this year from the ongoing study," commented Dr. Jan Fagerberg, Micromet's Chief Medical Officer. "We expect that the positive risk/benefit profile of blinatumomab in ALL will pave the way for a pivotal trial and a fast track to market in this indication."

(1) Topp, M. et al. (2009). Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL). ASH Annual Meeting, abstract no. 840

About BiTE Antibodies

BiTE® antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER
2. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
3. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
4. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
5. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
6. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
7. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
8. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
9. QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
10. White Paper Explains Aspects of Testing From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product
11. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... PHILADELPHIA , April 24, 2015  Lannett Company, ... has amended and increased its five-year revolving credit facility ... includes an accordion feature that will allow the company ... an additional $30.0 million, subject to securing additional commitments ... date of the credit facility remains December 18, 2018. ...
(Date:4/23/2015)... 24, 2015  AbbVie (NYSE: ABBV ) has ... has accepted its New Drug Application (NDA) and granted ... antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin ... with chronic genotype 4 (GT4) hepatitis C virus (HCV) ... interferon-free therapy being evaluated by the FDA for patients ...
(Date:4/23/2015)... Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that ... on Thursday, May 7, 2015, after the close of ... audio webcast immediately following the announcement at 4:30 p.m. ... results and provide a business and financial update. ... via the Investors & Media section of the Jazz ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 2
... 2010 TechniScan, Inc. (OTC Bulletin Board: ... development and commercialization of an automated breast ultrasound imaging system, ... TechniScan entered into amendments with each note holder, effective as ... its entire portfolio of secured convertible promissory notes from October ...
... 8, 2010 Arstasis is pleased to announce that ... Registry Evaluating Closure Following Access with the Arstasis One ... anticipated to enroll up to 500 patients in at ... is to observe the clinical safety and effectiveness of ...
Cached Medicine Technology:TechniScan, Inc. Announces Restructuring of Convertible Debt 2Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years 2Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years 3
(Date:4/24/2015)... New York (PRWEB) April 24, 2015 ... to move forward in the federal multidistrict litigation ... Carolina. According to court documents, the parties involved ... on April 16th detailing, among other things, preparation ... notes that counsel for both plaintiffs and defendants ...
(Date:4/24/2015)... 24, 2015 The first step to ... mind. , For meditation and yoga teacher Stine Koppernæs, ... been invaluable tools that allow her to experience more ... has been a teacher since 2006, and through the ... state of being. , “I love sharing this way ...
(Date:4/24/2015)... 24, 2015 Anchor Health Administrators (Anchor), ... Professionals, today announced their exclusive agreement with LTC Solutions ... Care Insurance distribution partner. , Anchor has more than ... Insurance benefits for associations, and is currently the designated ... Long Term Care Insurance member benefit. , “I am ...
(Date:4/24/2015)... Fla. (PRWEB) April 24, 2015 “Kind,” ... healer” were among the ways Denise Weiner described pediatric ... who cared for her daughter, Alexa, during her five-year ... brain resections, a bone marrow transplant and numerous experimental ... house to visit Alexa when she was not in ...
(Date:4/24/2015)... National Access Cannabis (NAC), Canada’s ... medical cannabis, is taking a leadership role in ensuring ... , NAC is the first to back mdBriefCase Group ... NAC will be providing 300 healthcare professionals with free ... help Canadians gain safe and responsible access to medical ...
Breaking Medicine News(10 mins):Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 4Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2
... Awareness,Week approaches, 2009 brings yet another year of unhealthy ... Americans, including men and,boys. , ... eating,disorders is so important because hundreds of thousands of ... even consider an eating,disorder as a diagnosis for a ...
... and ,e-commerce feature to company Web site - www.geritrex.com . ... ... -- The Geritrex Corporation, a privately held pharmaceutical company that offers ... business. Founded by CEO and registered pharmacist Anthony Madaio, Geritrex ...
... tests for devastating conditions, report says , , WEDNESDAY, Feb. 18 ... three babies in the United States was born in a ... of conditions. But by the end of 2008, all 50 ... rules requiring newborn screening for at least 21 disorders, a ...
... RIVER, N.Y., Feb. 18 Tesia-PCI has successfully ... with United Concordia Companies, Inc., a national dental ... took just over two months from plan to ... experience and expertise helped United Concordia to avoid ...
... was announced today that,Medizone International,s (Pink Sheets: MZEI) ... direction of Dr. Michael E.,Shannon of the Canadian ... President of the Canadian Foundation for Global Health. ... Medizone International and is the Company,s,Director of Medical ...
... continues to present its myriad of challenges, SunStone ... cost cutting measures including cutbacks in capital projects, ... direct patient contact such as marketing, community, and ... easier layers to peel in these expense reduction ...
Cached Medicine News:Health News:Remuda Ranch Seeks to Increase Awareness of Eating Disorders Among Males During National Eating Disorders Awareness Week (NEDAW), February 22-28, 2009 2Health News:A "Healthy" Company - Geritrex Celebrates Its 30 Year Anniversary with New Rebranding Effort and Expanding Distribution Channels 2Health News:Newborn Screenings Now Required Across U.S. 2Health News:Newborn Screenings Now Required Across U.S. 3Health News:National Dental Insurer United Concordia Successfully Launches Real-Time Claims Processing with Tesia-PCI 2Health News:The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc. 2Health News:The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc. 3Health News:The Marketing Enigma 2
... occlusive wrap than VICRYL knitted mesh. Especially ... be contained. Predictable absorption. Polyglactin 910 has ... nonpyrogenic. ,VICRYL (polyglactin 910) woven mesh is ... glycolide and lactide, derived respectively from glycolic ...
... Line Reinforcement Material is a safe, ... air leaks and as such, the ... biocompatible, ePTFE material requires no pretreatment ... load and fire and the material's ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... ProLite Ultra™, the next generation of thin ... hernia surgery and general soft tissue repair. ... better handling and more flexible polyproplylene mesh, ... ProLite Ultra. Its unique Litemesh™ polypropylene microfilament ...
Medicine Products: